section name header

Pronunciation

thye-oh-RID-a-zeen

Classifications

Therapeutic Classification: antipsychotics

Pharmacologic Classification: phenothiazines

Indications

BEERS REMS


Action

  • Alters the effects of dopamine in the CNS.
  • Possesses significant anticholinergic and alpha-adrenergic blocking activity.
Therapeutic effects:
  • Diminished signs and symptoms of psychoses.

Pharmacokinetics

Absorption: Absorption from tablets is variable.

Distribution: Widely distributed, high concentrations in the CNS.

Protein Binding: 90%.

Metabolism/Excretion: Primarily metabolized by the liver via the CYP2D6 isoenzyme; the CYP2D6 isoenzyme exhibits genetic polymorphism (7% of population may be poor metabolizers and may have significantly thioridazine concentrations and an risk of adverse effects).

Half-Life: 21–24 hr.

Time/Action Profile

(antipsychotic effects)

ROUTEONSETPEAKDURATION
POunknownunknown8–12 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: ARRHYTHMIAS, hypotension, QT interval prolongation, tachycardia

Derm: photosensitivity, pigment changes, rash

EENT: blurred vision, dry eyes, lens opacities, pigmentary retinopathy (high doses)

Endo: amenorrhea, galactorrhea

GI: constipation, dry mouth, anorexia, drug-induced hepatitis, ileus

GU: priapism, urinary retention

Hemat: AGRANULOCYTOSIS, leukopenia

Metab: hyperthermia, weight gain

Neuro: sedation, extrapyramidal reactions, NEUROLEPTIC MALIGNANT SYNDROME, tardive dyskinesia

Misc: allergic reactions

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Mellaril